Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study - Papp, Kim; Bachelez, Herve; Costanzo, Antonio; Foley, Peter; Gooderham, Melinda; Kaur, Primal; Narbutt, Joanna; Philipp, Sandra; Spelman, Lynda; Weglowska, Jolanta; Zhang, Nan; Strober, Bruce (Journal of the American Academy of Dermatology, 2017)
Keywords: ABP 501; adalimumab; Adalimumab - therapeutic use; Adult; biosimilar; Biosimilar Pharmaceuticals - therapeutic use; Dermatology; Double-Blind Method; efficacy; equivalence; Female; Humans; Male; Middle Aged; psoriasis; Psoriasis - drug therapy; safety; Severity of Illness Index; PASI 90; equivalence; PASI; PASI 50; CI; PASI 75; TNF; ABP 501; adalimumab; efficacy; PASI 100; TEAE; psoriasis; safety; SAE; ADA; biosimilar; 50% or more improvement in Psoriasis Area and Severity Index score from baseline; treatment-emergent adverse event; Psoriasis Area and Severity Index; 100% improvement in Psoriasis Area and Severity Index score from baseline; 75% or more improvement in Psoriasis Area and Severity Index score from baseline; serious adverse event; 90% or more improvement in Psoriasis Area and Severity Index score from baseline; antidrug antibody; tumor necrosis factor; confidence interval